Alexander K Tsai

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Benign Prostatic Hyperplasia

Radical Prostatectomy

Artificial Intelligence

Ejection Fraction

Top Venues

Expert opinion on biological therapy

JCO oncology practice

JCO clinical cancer informatics

This page only lists publications with an associated author ORCID identifier.

Publications

Alexander K Tsai, Sana Kagalwalla, Jenna Langer, Thuy Le-Kumar, Vikas Le-Kumar, Emmanuel S Antonarakis
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations. Expert opinion on biological therapy (2024)
Alexander K Tsai, Sana Kagalwalla, Jenna Langer, Thuy Le-Kumar, Vikas Le-Kumar, Emmanuel S Antonarakis
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations. Expert opinion on biological therapy 24 (1-2) (2024)
Alexander K Tsai, Sana Kagalwalla, Jenna Langer, Thuy Le-Kumar, Vikas Le-Kumar, Emmanuel S Antonarakis
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations. Expert opinion on biological therapy 24 (1-2) (2024)
Alexander K Tsai, Sana Kagalwalla, Jenna Langer, Thuy Le-Kumar, Vikas Le-Kumar, Emmanuel S Antonarakis
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations. Expert opinion on biological therapy (2024)
Vishal R Patel, Alexander K Tsai, Anne H Blaes, Ravi B Parikh, Adewole S Adamson, Arjun Gupta
Association Between Price and Appropriateness of Cancer-Related Medical Information Generated by Chat-Based Artificial Intelligence Models. JCO clinical cancer informatics 7 (2023)
Vishal R Patel, Vidhyalakshmi Ramesh, Alexander K Tsai, Ramy Sedhom, Westanmo Anders, Anne H Blaes, Rachel Isaksson Vogel, Helen M Parsons, Timothy P Hanna, Ishani Ganguli, Stacie B Dusetzina, Gabrielle Betty Rocque, Christopher M Booth, Arjun Gupta
Health Care Contact Days Experienced by Decedents With Advanced GI Cancer. JCO oncology practice (2023)
Alexander K Tsai, Ingunn M Stromnes
CD39 deletion in TCR-engineered T cells enhances antitumour immunity. Gut (2023)